Isomorphic Labs Raises $5 Billion to Push Drug Candidates Into Trials
Isomorphic Labs raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, funding simulation-based drug design, more medicine programs and a push toward clinical trials.
By Daniel Okafor
3 min read

What's News
- $5 billion Series C round co-led by Greenoaks and Sequoia Capital.
- Andreessen Horowitz was a new investor; GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also invested.
- $2.1 billion Series B in May; the two disclosed rounds total $7.1 billion.
- Isomorphic Labs was spun out of Google’s DeepMind in 2021.
- $50 billion was the reported fundraising valuation; Isomorphic Labs did not disclose the final valuation.
Isomorphic Labs raised $5 billion in a Series C round to move drug candidates toward clinical trials, Bloomberg reported. Isomorphic Labs did not disclose the transaction’s valuation, although Bloomberg reported earlier this month that the company was seeking funding at a $50 billion valuation.
Who backed the round?
The Series C brought co-leads Greenoaks and Sequoia Capital, new investor Andreessen Horowitz and all of Isomorphic Labs’ existing backers, according to Bloomberg. Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also invested.
How does the drug-design engine work?
Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models to explore various areas of chemistry and help the company design drugs, according to the company. The approach builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, Bloomberg said.
Bloomberg described AlphaFold as a system that predicts the 3D structure of proteins from their genetic sequence alone. Isomorphic Labs extends that protein-modeling foundation into a broader engine for exploring chemistry and designing drugs.
Isomorphic Labs said its program has yielded “positive preclinical results” in oncology and immunology. The statement places the program before clinical trials, while the round’s stated purpose is to move candidates into those trials.
The company has also struck pharmaceutical deals with Eli Lilly, Novartis and Johnson & Johnson, Bloomberg reported. The funding announcement did not disclose the financial terms, candidate names or trial schedules attached to those agreements.
What will the $5 billion fund?
Isomorphic Labs will use the proceeds to continue developing its drug-design engine and to extend its work into more types of medicine, the company said. Clinical development is the next stated milestone, with the company seeking to take candidates into trials rather than stopping at preclinical findings.
The Series C follows a $2.1 billion Series B round in May, Bloomberg reported. The two disclosed financings total $7.1 billion. The new round is about 2.4 times the size of the May financing, according to Bloomberg’s reported terms.
Why did the founder change roles?
Isomorphic Labs was spun out of Google’s DeepMind in 2021, Bloomberg reported. The Series C is its first fundraise since founder and CEO Demis Hassabis left his post as head of DeepMind to focus on drug discovery. Hassabis also moved into a chairman role at DeepMind.
Hassabis and John Jumper, then DeepMind’s director, won the Nobel Prize in chemistry for the lab’s work on AlphaFold, Bloomberg said. AlphaFold’s sequence-based protein prediction supplies the scientific foundation that Isomorphic Labs’ drug-design engine builds on.
What does the $50 billion figure mean?
The $50 billion number was a reported fundraising valuation, not a disclosed price for the completed Series C. Isomorphic Labs withheld its new valuation, Bloomberg said, so the final transaction valuation remains unconfirmed in the company’s announcement.
The confirmed financing is $5 billion. The reported target valuation is $50 billion. Investors therefore have a committed round size but no verified company valuation from the disclosure.
The immediate test is whether Isomorphic Labs can convert its reported oncology and immunology findings into drug candidates entering clinical trials. Its expansion into additional areas of medicine will show whether the simulation engine can support the wider programs funded by the round.
Original: isomorphiclabs.com
More from Daniel Okafor
Show full bio
Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.
2,216 articles